#DMPK

[kosheeka]

Want to take your liver models to the next level? Incorporate primary hepatocytes for more realistic and accurate results.

Product details: https://kosheeka.com/product/human-hepatocytes-in-suspension/

[eurofinsadvinus]

Dr. Lalitha Vijayakrishnan and Ms. Pujitha Reddy will be at the ACE Drug Discovery Summit, 2-3 March 2023 at The Insurance Hall, London. Looking forward to fantastic conversations and new potential opportunities. If you will be in the city or at the event and would like to schedule a meeting to discuss your drug discovery and development requirements, email us at bd@advinus.com

[sravanms]

Innovating HealthCare Solutions: Aryastha Life Sciences Pioneers Drug Discovery and Development

Aryastha Life Sciences, headquartered in Hyderabad's renowned Genome Valley, is at the forefront of revolutionizing the pharmaceutical industry. Specializing in drug discovery and development services, Aryastha offers a comprehensive suite of solutions aimed at addressing critical healthcare challenges.

With a focus on medicinal chemistry and drug discovery, Aryastha leverages cutting-edge technologies and interdisciplinary approaches to identify novel therapeutic targets and develop innovative drug candidates. The organization's robust Discovery Chemistry and Discovery Biology services enable the rapid optimization of lead compounds, paving the way for the development of new drugs to combat various diseases.

Aryastha's commitment to advancing cancer research is evident through its Oncology Services, which encompass target identification, lead optimization, and preclinical evaluation of anti-cancer agents. Through strategic collaborations and pioneering research initiatives, Aryastha aims to bring promising oncology therapies to market, providing hope to patients worldwide.

Moreover, Aryastha's Immunology Services play a crucial role in the development of immunotherapies and biologics for the treatment of autoimmune disorders and infectious diseases. The organization's expertise in immunology, coupled with state-of-the-art facilities, enables the rapid assessment of drug candidates' efficacy and safety profiles.

In addition to its discovery-focused services, Aryastha offers Pre-Clinical DMPK (Drug Metabolism and Pharmacokinetics) and Development Services, facilitating the transition of drug candidates from preclinical studies to clinical trials. Through rigorous testing and optimization, Aryastha ensures that its clients' drug candidates meet regulatory standards and exhibit optimal pharmacokinetic properties.

Aryastha Life Sciences is dedicated to driving innovation in drug discovery and development, with a vision to improve global healthcare outcomes. By combining scientific expertise, technological innovation, and a commitment to excellence, Aryastha continues to redefine the boundaries of pharmaceutical research and development, ultimately benefiting patients worldwide.

[srablog]

Drug Discovery and Development Services | Pre Clinical DMPK Services | Aryastha

Explore Aryastha's robust Drug Discovery and Development Services. Our adept team specializes in advanced Pre Clinical DMPK Services, ensuring a smooth progression from drug conception to development.

[blogsibd]

Innovating HealthCare Solutions: Aryastha Life Sciences Pioneers Drug Discovery and Development

Aryastha Life Sciences, headquartered in Hyderabad's renowned Genome Valley, is at the forefront of revolutionizing the pharmaceutical industry. Specializing in drug discovery and development services, Aryastha offers a comprehensive suite of solutions aimed at addressing critical healthcare challenges.

With a focus on medicinal chemistry and drug discovery, Aryastha leverages cutting-edge technologies and interdisciplinary approaches to identify novel therapeutic targets and develop innovative drug candidates. The organization's robust Discovery Chemistry and Discovery Biology services enable the rapid optimization of lead compounds, paving the way for the development of new drugs to combat various diseases.

Aryastha's commitment to advancing cancer research is evident through its Oncology Services, which encompass target identification, lead optimization, and preclinical evaluation of anti-cancer agents. Through strategic collaborations and pioneering research initiatives, Aryastha aims to bring promising oncology therapies to market, providing hope to patients worldwide.

Moreover, Aryastha's Immunology Services play a crucial role in the development of immunotherapies and biologics for the treatment of autoimmune disorders and infectious diseases. The organization's expertise in immunology, coupled with state-of-the-art facilities, enables the rapid assessment of drug candidates' efficacy and safety profiles.

In addition to its discovery-focused services, Aryastha offers Pre-Clinical DMPK (Drug Metabolism and Pharmacokinetics) and Development Services, facilitating the transition of drug candidates from preclinical studies to clinical trials. Through rigorous testing and optimization, Aryastha ensures that its clients' drug candidates meet regulatory standards and exhibit optimal pharmacokinetic properties.

Aryastha Life Sciences is dedicated to driving innovation in drug discovery and development, with a vision to improve global healthcare outcomes. By combining scientific expertise, technological innovation, and a commitment to excellence, Aryastha continues to redefine the boundaries of pharmaceutical research and development, ultimately benefiting patients worldwide.

[cdmoservices]

[dmpk]

https://www.dueclix.com/dmpk

[neha24blog]

Preclinical CRO Market Outlook On The Basis Of Service, Model Type, End-Use, Region And Forecast to 2030: Grand View Research Inc.

San Francisco, 17 Jan 2024: The Report Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Toxicology Testing, Bioanalysis & DMPK Studies), By End Use (Biopharmaceutical Companies, Government & Academic Institutes), And Segment Forecasts, 2023 – 2030 The global preclinical CRO market size is expected to reach USD 9.68 billion by 2030, expanding at a CAGR of 7.9%, according to…

[sudheervanguri]

Aragen Life Sciences Careers: Unlock Your Potential as a Research Associate in In Vitro ADME & DMPK Introduction: Discover a world of opportunities with Aragen Life Sciences, a leading organization dedicated to pioneering research and development. As we expand our team, we are excited to announce vacancies for skilled professionals in In Vitro ADME & DMPK. Explore the details below and embark on a rewarding career journey with us. About the Aragen Life Sciences: Aragen Life Sciences, at the forefront of scientific innovation, is committed to advancing healthcare through cutting-edge research. With a strong presence in Bangalore and Hyderabad, we offer an inspiring work environment for passionate individuals seeking to make a significant impact. Company Vacancies List: Join our dynamic team with the following vacancies: Position Title: Research Associate - In Vitro ADME Position Title: Associate Scientist DMPK Job Description: Research Associate - In Vitro ADME: Desired Qualification: 1-3 years CRO/Industry experience with a Master's in applied Sciences. Study design, execution, data analysis, and reporting of ADME studies. Experience in in vitro ADME studies using microsomes and hepatocytes. Conducting plasma stability, PPB, B/P ratio, etc., as per study protocols. Validation/standardization of in vitro assays. Ensure data integrity and adhere to good documentation practices. Associate Scientist DMPK: Desired Qualification: 7-10 years CRO/Industry experience with a Master's in applied Sciences. Expertise in handling rodents and conducting rodent PK studies independently. Proficient in various routes of administration and blood collection techniques. Expert in different cannulation techniques in rodents. Ability to perform PK modeling using WinNonline software. Interpret bioanalytical data, perform data interpretation, creation, and statistical analysis. How to Apply: If you possess the desired experience and skills, share your profile at prashanthi.adisai@aragen.com. Mention the specific role you are applying for in the subject line. Shortlisted candidates will be contacted for further processes.

[jobrxiv]

SENIOR RESEARCH SCIENTIST / PRINCIPAL RESEARCH SCIENTIST - DMPK Calibr at Scripps Research See the full job description on jobRxiv: https://jobrxiv.org/job/senior-research-scientist-principal-research-scientist-dmpk/?feed_id=47316 #ScienceJobs #hiring #research San Diego #UnitedStatesUS #Researcher #Scientist

[eurofinsadvinus]

Eurofins Advinus Discovery Services team is set to attend Discovery Europe 2023 in Berlin from June 6-7. We would like to invite you to visit us at booth 22. We look forward to sharing our latest advancements in discovery services and explore ways to help advance and accelerate your research. We offer integrated and/or stand-alone drug discovery services that include - Medicinal Chemistry, Analytical Chemistry, In Vitro Biology, Safety Pharmacology Studies and ADME/DMPK. To know more click on the link - https://lnkd.in/dJeKvzGs “It has been observed that fake employment offers are being made, via email and otherwise, by misusing Eurofins Advinus name. Please be informed that Eurofins Advinus does not require any payment or fees from prospective candidates and Eurofins Advinus does not send any recruitment email from generic email addresses other than email addresses ending with “advinus.com”. ”

[cdmoservices]

[chinemagazine]

Zion Pharma annonce un accord mondial avec Roche pour le développement et la commercialisation d'un inhibiteur

HONG KONG & SUZHOU, Chine & SHANGHAI--(BUSINESS WIRE)--Zion Pharma Limited, une société de biotechnologie chinoise axée sur le développement de composés pénétrant dans le cerveau, a annoncé ce jour que Roche a fait l'acquisition des droits mondiaux pour le principal programme de Zion, ZN-A-1041. ZN-A-1041 est un inhibiteur sélectif de la tyrosine kinase administré oralement ciblant le récepteur 2 du facteur de croissance épidermique humain (HER2). ZN-A-1041 a été conçu pour pénétrer la barrière hémato-encéphalique, et peut potentiellement traiter ou prévenir l'apparition de métastases au cerveau chez les patients atteints d'un cancer du sein métastatique HER2-positif. Jusqu'à 50 % des patients atteints d'un tel cancer développent des métastases au cerveau au cours de leur maladie. « L'accord conclu avec Roche est le fruit d'un excellent travail d'équipe visant à apporter aux patients atteints d'un cancer du sein HER2-positif un traitement appelé à devenir le meilleur de sa catégorie, en particulier pour traiter ou prévenir les métastases au cerveau grâce à sa capacité élevée à pénétrer la barrière hémato-encéphalique », a déclaré Zack Cheng, M.D., Ph.D., cofondateur, PDG et président du CA de Zion Pharma Limited. « En cinq ans à compter de sa création, notre société aura été capable d'atteindre le stade des premiers essais cliniques chez l'humain, et de trouver un partenaire comme Roche, qui possède les ressources et l'expertise pour fournir ZN-A-1041 aux patients n'ayant que peu d'options thérapeutiques », a ajouté le Dr Cheng. Et le Dr Ding Zhou, Ph.D., directeur scientifique et cofondateur de Zion Pharma Limited, d'ajouter : « nous sommes ravis que Roche ait identifié la capacité de notre premier produit à faire avancer le traitement de référence dans le domaine des composés pénétrant dans le cerveau pour le cancer du sein HER2-positif. » « Nous sommes impatients de commencer ce partenariat avec Zion afin de poursuivre le développement de cette option thérapeutique innovante pour les personnes atteintes d'un cancer du sein HER2-positif. Ce partenariat s'appuie sur l'expérience et l'expertise de Roche dans le traitement de ce type de cancer et soutient notre objectif, faire avancer la science en associant des innovations externes à nos capacités internes afin de combler des besoins encore non satisfaits », a affirmé James Sabry, directeur Monde de Pharma Partnering. Après une période de transition, Roche sera en charge du développement, de la fabrication et de la commercialisation de ZN-A-1041 à l'international. Zion recevra jusqu'à 70 millions d'USD en versements initiaux et à court terme en fonction de la réalisation de certaines étapes intermédiaires. Zion pourra également recevoir jusqu'à 610 millions d'USD en versements supplémentaires à la suite de la réalisation de certaines étapes de développement, réglementaires et commerciales pour ZN-A-1041, ainsi que des redevances progressives sur les ventes. À propos de ZN-A-1041 ZN-A-1041 est un inhibiteur sélectif de la tyrosine kinase administré oralement ciblant le récepteur 2 du facteur de croissance épidermique humain (HER2). ZN-A-1041 a été conçu pour pénétrer la barrière hémato-encéphalique. L'essai de phase 1 en cours se déroule sur plusieurs sites aux États-Unis et en Chine. De plus amples détails seront présentés aux sessions d'affichage à l'occasion de la conférence annuelle de l'American Society of Clinical Oncology en juin 2023. À propos de Zion Pharma Limited Zion Pharma est une société privée de biotechnologie au stade clinique axée sur le développement de nouveaux agents anti-tumoraux à petites molécules. Fondée en 2018, la société a son siège de recherche à Suzhou et d'autres sites de recherche à Shanghai. Elle applique une approche innovante d'invention de traitements en s'appuyant sur son expertise en DMPK pour développement de divers composés propriétaires premiers/meilleurs de leur catégorie orientés sur des cibles thérapeutiques favorisant l'inhibition des tumeurs, y compris la protéine mutée dans le syndrome d'ataxie télangiectasie (ATM), le Kirsten RAt Sarcoma (KRAS G12D) et le SMARCA2 (BRM). Pour de plus amples informations sur Zion Pharma, visitez le site www.zionpharma.com. Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence. Contacts Contact presse et partenaires : J. Michael French SVP Développement organisationnel michael.french@zionpharma.com +1.703.338.1972 Read the full article